• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利多卡因会使除颤能量需求出现可逆的、浓度依赖性增加。

Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements.

作者信息

Dorian P, Fain E S, Davy J M, Winkle R A

出版信息

J Am Coll Cardiol. 1986 Aug;8(2):327-32. doi: 10.1016/s0735-1097(86)80047-x.

DOI:10.1016/s0735-1097(86)80047-x
PMID:3734254
Abstract

To investigate the influence of lidocaine on the energy requirements for internal defibrillation, lidocaine (n = 8) or saline solution (n = 12) was administered by intravenous infusion to 20 pentobarbital-anesthetized dogs, and the likelihood of successful defibrillation was examined at various shock energy levels before and after treatment. After lidocaine administration to a mean steady state concentration of 5.6 +/- 2.7 micrograms/ml, the mean energy required to achieve 50 and 90% success in defibrillation (E50 and E90) increased by 61.1 +/- 34.1% (mean +/- SD, p less than 0.005) and 47.1 +/- 28.6% (p less than 0.005), respectively. The steady state log lidocaine concentration correlated positively with the observed increase in E50 (r = 0.887, p less than 0.01) over a concentration range from 1.95 to 9.8 micrograms/ml. In a related experiment, lidocaine infusion was administered to five dogs and then abruptly discontinued. At energy levels achieving a mean 90.0 +/- 10.0% success in defibrillation before treatment, only 43.3 +/- 23.4% success was achieved after 60 minutes of the lidocaine infusion (p less than 0.01) at a mean plasma concentration of 8.4 +/- 2.1 micrograms/ml. The percent of successful defibrillations returned to baseline value (92.0 +/- 18.0%, p less than 0.01) after drug washout at a time when mean lidocaine concentration had declined to 1.8 +/- 0.5 microgram/ml. Lidocaine causes a reversible, concentration-dependent increase in the energy requirements for successful defibrillation; recommendations to administer lidocaine to patients with ventricular fibrillation resistant to defibrillation may need to be reviewed.

摘要

为研究利多卡因对体内除颤能量需求的影响,将利多卡因(n = 8)或生理盐水(n = 12)静脉输注给20只戊巴比妥麻醉的犬,在治疗前后不同电击能量水平下检查除颤成功的可能性。利多卡因给药至平均稳态浓度5.6±2.7微克/毫升后,除颤成功率达到50%和90%时所需的平均能量(E50和E90)分别增加了61.1±34.1%(平均值±标准差,p<0.005)和47.1±28.6%(p<0.005)。在1.95至9.8微克/毫升的浓度范围内,稳态利多卡因浓度对数与观察到的E50增加呈正相关(r = 0.887,p<0.01)。在一项相关实验中,对5只犬输注利多卡因,然后突然停药。在治疗前除颤成功率平均为90.0±10.0%的能量水平下,利多卡因输注60分钟后,平均血浆浓度为8.4±2.1微克/毫升时,除颤成功率仅为43.3±23.4%(p<0.01)。药物洗脱后,当平均利多卡因浓度降至1.8±0.5微克/毫升时,除颤成功率恢复至基线值(92.0±18.0%,p<0.0

相似文献

1
Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements.利多卡因会使除颤能量需求出现可逆的、浓度依赖性增加。
J Am Coll Cardiol. 1986 Aug;8(2):327-32. doi: 10.1016/s0735-1097(86)80047-x.
2
Effect of quinidine and bretylium on defibrillation energy requirements.奎尼丁和溴苄铵对除颤能量需求的影响。
Am Heart J. 1986 Jul;112(1):19-25. doi: 10.1016/0002-8703(86)90672-1.
3
Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation.抗心律失常药物对犬除颤能量需求的评估。钠通道阻滞与动作电位延长。
Circulation. 1989 May;79(5):1106-17. doi: 10.1161/01.cir.79.5.1106.
4
Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: experimental studies.利多卡因和溴苄铵对经胸除颤能量需求的影响:实验研究
J Am Coll Cardiol. 1986 Feb;7(2):397-405. doi: 10.1016/s0735-1097(86)80512-5.
5
Effects of lidocaine on relation between defibrillation threshold and upper limit of vulnerability in open-chest dogs.利多卡因对开胸犬除颤阈值与易损性上限关系的影响。
Circulation. 1992 Mar;85(3):1146-51. doi: 10.1161/01.cir.85.3.1146.
6
Ventricular defibrillation in canines with chronic infarction, and effects of lidocaine and procainamide.慢性梗死犬的心室除颤以及利多卡因和普鲁卡因胺的作用
Pacing Clin Electrophysiol. 1993 Feb;16(2):337-46. doi: 10.1111/j.1540-8159.1993.tb01585.x.
7
Effects of flecainide on defibrillation thresholds in the anesthetized dog.氟卡尼对麻醉犬除颤阈值的影响。
J Am Coll Cardiol. 1989 Sep;14(3):777-81. doi: 10.1016/0735-1097(89)90125-3.
8
pH-dependent effects of lidocaine on defibrillation energy requirements in dogs.利多卡因对犬除颤能量需求的pH依赖性效应
Circulation. 1989 Oct;80(4):1003-9. doi: 10.1161/01.cir.80.4.1003.
9
Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs.抗心律失常药物使犬心室除颤阈值升高。
Am Heart J. 1979 Sep;98(3):345-50. doi: 10.1016/0002-8703(79)90047-4.
10
The relationship between successful defibrillation and delivered energy in open-chest dogs: reappraisal of the "defibrillation threshold" concept.开胸犬成功除颤与释放能量之间的关系:对“除颤阈值”概念的重新评估。
Am Heart J. 1987 Jan;113(1):77-84. doi: 10.1016/0002-8703(87)90012-3.

引用本文的文献

1
Atrial Fibrillation in Patients with Congenital Heart Disease.先天性心脏病患者的心房颤动
J Atr Fibrillation. 2017 Jun 30;10(1):1612. doi: 10.4022/jafib.1612. eCollection 2017 Jun-Jul.
2
Anti-arrhythmics in out-of-hospital cardiac arrest: lessons from a randomized controlled trial.院外心脏骤停中的抗心律失常药物:一项随机对照试验的经验教训
J Thorac Dis. 2016 Oct;8(10):E1307-E1310. doi: 10.21037/jtd.2016.10.59.
3
Resuscitation Outcomes Consortium-Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.
复苏结局联合会-胺碘酮、利多卡因或安慰剂研究(ROC-ALPS):院外心脏骤停抗心律失常药物试验背后的原理和方法。
Am Heart J. 2014 May;167(5):653-9.e4. doi: 10.1016/j.ahj.2014.02.010. Epub 2014 Mar 1.
4
Incidence and clinical predictors of low defibrillation safety margin at time of implantable defibrillator implantation.植入式心脏除颤器植入时低除颤安全裕度的发生率及临床预测因素
J Interv Card Electrophysiol. 2012 Jun;34(1):93-100. doi: 10.1007/s10840-011-9648-z. Epub 2012 Mar 6.
5
Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation.
Curr Cardiol Rep. 2002 Sep;4(5):434-40. doi: 10.1007/s11886-002-0044-2.
6
Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias.抗心律失常药物与植入式除颤器治疗心房和心室快速性心律失常的相互作用。
Curr Cardiol Rep. 1999 Nov;1(4):282-8. doi: 10.1007/s11886-999-0051-7.
7
Combining antiarrhythmic drugs and implantable devices therapy: benefits and outcome.抗心律失常药物与植入式器械治疗相结合:益处与结果。
J Interv Card Electrophysiol. 2000 Jan;4 Suppl 1:65-8. doi: 10.1023/a:1009874330416.
8
Effect of general anesthesia on the defibrillation energy requirement in patients undergoing defibrillator implantation.
J Interv Card Electrophysiol. 1999 Dec;3(4):325-8. doi: 10.1023/a:1009831802964.
9
The 1998 European Resuscitation Council guidelines for adult advanced life support. Advanced Life Support Working Group of the European Resuscitation Council.1998年欧洲复苏委员会成人高级生命支持指南。欧洲复苏委员会高级生命支持工作组。
BMJ. 1998 Jun 20;316(7148):1863-9.
10
Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST.I类抗心律失常药物的亚分类:CAST研究后相关性增强
Cardiovasc Drugs Ther. 1992 Oct;6(5):519-28. doi: 10.1007/BF00055611.